Investor Relations Presentation

September 2020

Forward Looking Statements & Non-GAAP Financial Measures

This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor

provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are

based on management’s beliefs and assumptions in light of information currently available to management. Accordingly, the

Company’s actual results may differ materially from those expressed or implied in such forward-looking statements due to

known or unknown risks and uncertainties that exist in the Company’s operations and business environment, including,

among other factors, those described in documents filed by the Company with the Securities and Exchange Commission,

specifically its Form 10-Ks and 10-Qs. The Company does not assume any obligation to update, amend or clarify such

statements to reflect new events, information or circumstances after the date of this presentation.

During the course of this presentation, certain non-GAAP financial information will be presented.

A reconciliation of those numbers to GAAP financial measures is available on the company’s website at www.aptar.com on

the Investor’s page (click on Events & Presentations / Presentations).

2

Overview

3

SALES BY REGION

55%32%

7%

6%

ATTRACTIVE END MARKETS

SERVING BEST KNOWN GLOBAL &

LOCAL BRANDS

DIVERSIFIED PORTFOLIO

RESEARCH AND IP-DRIVEN

Aptar Snapshot

1,250Patent Families

Approximately3%R & D

Of Annual Revenue

THE LEADER IN CONSUMER

DISPENSING AND DRUG DELIVERY

75-year history of innovation

Providing brand differentiation and

consumer / patient convenience

Consistent long-term focus, stability

and financial results

“We reimagine packaging solutions to

improve everyday life for people everywhere.”

$2.9 bil*

4

*2019 Annual Revenue

Examples of Products Counting on Aptar Drug Delivery and Dispensing Solutions (many are critical during the pandemic)

5

Rescue Drugs and

Therapies

Preventive Medicines

and Diagnostics Hand Sanitizers

Disinfectants Infant Nutrition

Pantry Staples

Pharma Beauty + Home Food + Beverage

6

Leveraging Deep Industrial and Product Knowhow Globally Across Three Reporting Segments

6* - LTM = Last twelve months ending June 30, 2020; the EBITDA %’s of LTM values are calculated on total Segment Adjusted EBITDA and exclude Corporate Expenses

Common Technologies and Solutions… …Serving Three Market-facing Reporting Segments

Core Manufacturing Technologies1

Best-in-Class Products and Services2

Aimed at Global Megatrends3

Precision Injection Molding

High-Speed Assembly

Metal Processing + Decorating

Material Science/Active Packaging

Dispensing and Delivery

Sealing

Active Packaging

✓ Sustainability

✓ Health + Wellness

✓ Connectivity

✓ Urbanization

✓ Changing Demographics

✓ e-Commerce/Individualization

% of Total LTM* Sales % of Total LTM* EBITDA

41%

45%

14%

67%

23%

10%

35%

EBITDA

Margin

11%

EBITDA

Margin

16%

EBITDA

Margin

7

• While there is uncertainty due to the effects of COVID-19,

we continue to invest in our company for the long-term

• Product innovations serve the greater good of society

• The initial re-openings resulted in improved demand for

certain products toward the end of the second quarter

• Strong cash generation, above prior year levels

• Focus on providing tangible value to patients, end

consumers and many of the world’s leading brands

1H 2020 Recap

20%Adjusted EBITDA

Margin

(vs 21% 1H 2019)

+9%Increase in Free

Cash Flow (FCF)

over prior year

-4%Decrease in Core

Sales from prior

year

Recent Announcements

8

8

Welcomed Kimberly Chainey to

our Executive Committee as EVP,

Global General Counsel

Launched our 2019 Sustainability Report;

highlights our aspirations, safety programs,

societal impact of products and community

outreach initiatives

FusionPKG acquisition is off to a great

start; benefitting from their ability to adapt

rapidly to the changing beauty demands

and consumer insights

Reporting Segment Reviews

9

Aptar Pharma Today

10

SALES BY REGION (2020)

66%29%

2%

3%

SALES BY MARKET (2020)

45%

23%

20%

12% Prescription

Consumer HealthCare

Injectables

Active Packaging

CUSTOMERS (Approx. 1500)

INNOVATIVE SOLUTIONS

PATENTS

PATIENT / CONSUMER

EXPERIENCE

8 BillionOver

Solutions per Year

750Patent Families

Managing close to

Successful long-term track record with over

150 approved NDAs, ANDAs and INDs in

past five years

10

Leader in Delivery Systems for Traditional Therapies

11

Nasal Delivery Solutions Eye Care Delivery Solutions Pulmonary Delivery Solutions

Global leader in nasal devices

for Allergic Rhinitis, Aptar

Pharma delivers across a wide

spectrum of nasal needs, from

respiratory and allergy

treatments to vaccines and

crisis medications.

Global leader in aerosol metering

valves for pressurized metered dose

inhalers (pMDIs). We address the

Asthma and COPD therapy markets

with a broad range of devices based

on metering valves for pMDIs, Dry

Powder Inhalers (DPIs), Breath

Actuated Inhalers (BAIs), and

mechanical and electronic add-on

devices.

The Ophthalmic Squeeze Dispenser

is the leading device for

preservative-free multidose

prescription medications and OTC

eye care products. It is accepted by

regulatory authorities worldwide

with close to 250 market references

launched globally.

Growing in the Injectables Market

12

Proven injectables partner

• 550+ customers in 70+ countries

worldwide

• Working with all of the top 10

Pharma players in injectables

• 70 of the 100 top molecules,

mostly life saving treatments

COVID-19 Opportunities

• > 100 injectable vaccines /

antiviral treatments being explored

• Increase in emergency / antibiotics

treatments

• QuickStart™ turnkey solution for

clinical development

Added-value solutions to meet most

stringent market requirements

around the development of complex

& highly sensitive drug formulations

• PremiumCoat™

• Premium Fill®

• Premium Vision™

Global manufacturing network

expansion to meet fast

growing demand

Expanding Our Pharma Services Platform

13

Foundation for Future Growth: Support through every step of the drug development journey

Guiding you through every step of drug product development

Device &

formulation

development

Clinical trialsRegulatory

filings

Market launch &

post-launch

A global leader in

patient onboarding

and adherence

programs.

A leading provider of

orally inhaled &

nasal drug product

design & development

services.

A full-service cGMP

lab specializing in

analytical testing of

drug delivery

systems.

A full-service cGMP lab

providing industry-

leading particulate

detection & predictive

analytical services.

A global provider of

innovative

drug delivery

systems and service

solutions.

Aptar Pharma Services

14

Growth from Repurposed and New Drug Launches Across a Variety of Delivery Methods

Bidose Nasal Spray Device

(Anti-depressant therapy)

Nasal Unidose Device

(Epilepsy seizure treatment)Protective Active Packaging Container and

Unidose Powder System Device

(Severe hypoglycemia treatment)

Activ-Blister™ Packaging Solution for Oral

Solid Dose

(HIV prevention medicine)

14

Recent examples:

Aptar Pharma

6 Mos. YTD 2020 Results

(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,

depreciation and amortization) excludes restructuring costs,

acquisition costs, non-recurring purchase accounting adjustments.

Metric3 Year

Average

YTD

2020

Long-term

Target

Core sales growth1 10% 6% 6-10%

Adj. EBITDA2 margin 35% 36% 32-36%

15

$555$598

$0

$200

$400

$600

YTD 2019 YTD 2020

$ in m

illio

ns

Sales

Reported

+8%

Core

6%

Acquisitions

3%

Currency

Effects

-1%

36% 36%

0%

10%

20%

30%

40%

YTD 2019 YTD 2020

Adjusted EBITDA(2) Margin%

SALES BY REGION (2020)

54%28%

11%

7%

SALES BY MARKET (2020)

45%

47%

8%

Beauty

Personal Care

Home Care

CUSTOMERS (6,000+)

INNOVATIVE SOLUTIONS

PATENTS

CONSUMER EXPERIENCE

16 BillionOver

Solutions per year

400Patent Families

Aptar Beauty + Home Today

Over

A significant amount of Europe sales end up in Asia in

luxury and travel

16

Beauty Home Care StaplesPersonal Care Essentials

Global leader in the beauty packaging

industry, known for combining

functional dispensing with premium

aesthetics. We provide solutions for

the luxury facial skin care, cosmetic

and perfumery markets, as well as

turnkey solutions ideal for indie

brands and the fast beauty market.

Providing a wide variety of solutions

for liquid soaps, hand sanitizers, sun

protection, hair care products and

body lotions. Sustainability is a focus

and in addition to using PCR, Aptar’s

pumps are currently being used on

refillable personal care products for

TerraCycle’s Loop platform.

Full range of dispensing systems for

staples such as surface cleaners

and disinfectants, air fresheners,

and pet care.

Broad Portfolio of Brand-differentiating Solutions

17

Strategic Steps to Strengthen Our Beauty Business

18

BTY

• Recently acquired a 49% equity

interest in BTY

• Leading Chinese manufacturer of high

quality, decorative metal components,

metal-plastic sub-assemblies, and

complete color cosmetics packaging

solutions for the beauty industry

Ongoing Footprint Consolidation

• We are closing our Stratford and Torrington

(CT) sites in the US, and our Ballinasloe

site in Ireland; will absorb and rationalize

production capacities into existing other

facilities

• Better positions us to serve our customers

and focus on long-term, profitable growth

• Continuation of other steps we have made

to streamline our Beauty + Home footprint

(facility consolidations in India, Argentina

and Southeast Asia, and sale of molding

facility in the US)

FusionPKG

• Recently acquired FusionPKG, leader in high

quality, prestige airless and color cosmetics

packaging, with conception-to-launch and

turnkey solutions for the North American

beauty market

• Proven creativity, engineering, formulation and

fast go-to-market capabilities – ‘fast-beauty’

• Existing relationships with both global

cosmetic and skin care customers and with

many indie brands

• Potential to scale this beyond North America

to other regions

Aptar Beauty + Home

6 mos. YTD 2020 Results

(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,

depreciation and amortization) excludes restructuring costs,

acquisition costs, non-recurring purchase accounting

adjustments.

Metric3 Year

Average

2020

YTD

Long-term

Target

Core sales growth(1) 3% -11% 3-6%

Adj. EBITDA(2) margin 13% 9% 15-17%

19

$710

$624

$0

$200

$400

$600

$800

YTD 2019 YTD 2020

$ in m

illio

ns

Sales

Reported

-12%Core

-11%

Acquisitions

2%

Currency

Effects

-3%

14%

9%

0%

4%

8%

12%

16%

YTD 2018 YTD 2019

Adjusted EBITDA(2) Margin %

SALES BY REGION (2020)

29%57%

7%

7%

SALES BY MARKET (2020)

73%

27%Food

Beverage

CUSTOMERS (>200 clients with top 20 representing 65% of sales)

INNOVATIVE SOLUTIONS

PATENTS

CONSUMER EXPERIENCE

Aptar Food + Beverage Today

7 BillionOver

Solutions per Year

150Patent Families

Over

20

Food Protection

Aptar Food + Beverage is setting new

standards to improve food safety. Our

active packaging technology protects

fresh cut produce and fresh seafood

from harmful pathogens like bacteria,

fungi and viruses.

On-The-Go Beverage

Aptar serves the beverage market

by providing closures for sports

drinks, drinkable dairy, juices and

bottled water. We reinvent and

improve the drinking experience

with tethered caps, child-friendly

closures and e-commerce ready

solutions.

Fridge and Pantry Staples

Aptar Food + Beverage uses our

innovative technologies to reinvent

everyday staples. Our solutions

provide product differentiation for

customers on the grocery store

shelf and improved functionality for

the end user.

Consumer-focused, Value-driven Applications

21

Sustainable and Convenient Solutions

Tethered Solutions

Our tethered solutions improve the

recyclability of bottle caps as they

stay connected to the bottle

throughout its lifecycle.

Flexible Packaging

As a leader in the development of flexible

package dispensing, we are helping

customers increase their market share with

innovative, best-in-class pouch fitments

(sealing and tamper evidence) and flow-

controlling dispensing solutions.

22

Aptar Food + Beverage

6 mos. YTD 2020 Results

(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,

depreciation and amortization) excludes restructuring costs,

acquisition costs, non-recurring purchase accounting

adjustments.

Metric

3 Year

Average 2020

Long-term

Target

Core sales growth(1) 5% -9% 6-10%

Adj. EBITDA(2) Margin 16% 17% 18-21%

23

$223

$198

$0

$60

$120

$180

$240

YTD 2019 YTD 2020

$ in m

illio

ns

Sales

Reported

-11%

Core

-9%

Acquisitions

0%

Currency

Effects

-2%

17% 17%

0%

5%

10%

15%

20%

YTD 2019 YTD 2020

Adjusted EBITDA(2) Margin %

Appendix

24

Compounding Growth Story

2009 - 2019

25

+4.5%CAGR

Core Sales

+8%CAGR

Adjusted EPS

+9%CAGR

Dividend

• average yield over 10

years = 1.6%

• 27 consecutive years

of paying increased

annual dividends

Strategic Priorities

Macro

Trends

• Aging Population

• Connectivity

• E-Commerce Supply Chain

• Health and Wellness

• Sustainability

• Urbanization

• Rise of Eastern Economies

• Shareholder Engagement

2017Financial (five year avg)

Sales Growth 3%

EBITDA Margin 19%

AcquisitionsStrategic technologies in the

US and EU

TalentEvolving need for greater

capabilities and diversity

Geographic FocusAmericas & EU

Strategic Priorities

2022Financial Sales Growth 4-7%

EBITDA Margin 20-22%

Acquisitions/PartnersGlobal acquisitions, partnerships,

incubators, new business models

TalentGreater diversity, inclusion and

global capabilities

Geographic FocusAdded emphasis on Asia/Middle

East/Eastern EU

26

3% (2019), - 4% (2020 YTD)

Board, CHRO, EVP General Counsel,

Asian Leadership, Strategy/ M&A,

Innovation, Digital , Diversity Targets

External Benchmarks, Innovation Pipeline,

Performance Mgmt, 6σ, Sustainability

Higher Growth, Beauty + Home and

Aptar Margin Expansion

CSP Technologies, FusionPKG, BTY,

Sonmol, Nanopharm, Reboul, Gateway,

Noble, PureCycle, Loop, Nippon Closures

O r g a n i c

G r o w t h

T a l e n t &

L e a d e r s h i p

E x c e l l e n c e

P i l l a r s

T r a n s f o r m a t i o n

A c q u i s i t i o n s &

P a r t n e r s h i p s

Revenue Near-term Sensitivity Related to COVID-19

27

Our Markets % of Revenue* Key Drivers

Pharma 38% Stable across most medicines and categories; Most prescription drugs and OTC

products are easily available for delivery; Potential upside should injectable

treatments be developed / grow.

Home Care 4% Stable across most categories; Potential upside with increased demand for cleaners.

Food 10% Major categories such as Condiments, Dairy and Infant Nutrition are stable; Food

Service (certain closures and trays) negatively impacted by confinement and

restaurant closings.

Personal Care 19% Major categories such as Grooming (including Haircare, Shaving) and Sunscreens

are negatively impacted by confinement; Partially offset by higher demand for

sanitizers and soaps.

Beverage 5% Majority of Beverage business is related to on-the-go beverages, including functional

beverages and premium bottled water, all negatively impacted from confinement.

Beauty 24% Prestige and Mass Beauty products significantly impacted by reduced travel (travel

retail sales), confinement and store closings (less usage, less opportunity to purchase

and e-commerce volumes not offsetting retail product sales declines).

Q1: Crisis

Early

Stage

Q2: Crisis

Low PointH2: Gradual Recovery

Magn

itude o

f Im

pact

Least

Affected

Most

Affected

* Based on 2019 annual sales

Six Months Year-to-Date 2020 Reported Results

28

YTD Highlights

• Pharma segment continued to report

strong year-on-year core sales growth

• Beauty + Home and Food + Beverage

segments experienced a more difficult first

half of the year primarily due to the

impacts of COVID-19

• Saw progressive signs of improvement for

Beauty + Home since the low point in April

• Beauty + Home was negatively impacted

by reduced orders due to lower prestige

beauty sales

• Food + Beverage experienced a decline

due to lower on-the-go beverage and food

service sales due to many people dining

at home and the passing through of lower

resin costs to customers

-4%Core Sales

Growth*

-2%Currency

Effects

+2%Acquisitions

29%YTD 2019

Reported

Effective Tax

Rate

30%YTD 2020

Reported

Effective Tax

Rate

* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures.

$1,487 $1,421

$0

$500

$1,000

$1,500

$2,000

YTD 2019 YTD 2020

Reported YTD Sales(in millions $)

-4%$2.08

$1.47

$-

$1.00

$2.00

$3.00

YTD 2019 YTD 2020

Reported YTD EPS

-29%

Adjustments:

• 2019: Restructuring initiatives of $11.3 mil;

transaction costs related to acquisitions of $1.1 mil

• 2020: Restructuring initiatives of $12.2 mil;

Transaction costs related to acquisitions of $4.6

mil; Purchase accounting adjustments of $1.3 mil

* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures.

Six Months Year-to-Date 2020 Adjusted EPS and Adjusted EBITDA

29

29%YTD 2019Effective Tax

Rate Adjusted

Earnings*

29%YTD 2020Effective Tax

Rate Adjusted

Earnings*

YTD Adjusted EPS and

Adjusted EBITDA Highlights

• Adjusted EPS and Adjusted EBITDA

were negatively impacted by:

• Lower sales volumes due to

COVID-19 pandemic mainly

impacting Beauty + Home

(prestige beauty applications)

and Food + Beverage (on-the-

go beverage closures)

• $7.2 million of Thank You

Award costs

$2.18

$1.72

$-

$1.00

$2.00

$3.00

YTD 2019 YTD 2020

Adjusted YTD EPS*

-21%$315

$281

$0

$100,000

$200,000

$300,000

$400,000

YTD 2019 YTD 2020

Adjusted YTD EBITDA(in millions $)

-11%

Free Cash Flow and Capital Allocation

30

Highlights

• Balance sheet remains strong and we have

generated more cash flow in the first six

months of 2020 than in the prior year,

primarily due to improvements in working

capital

• We have a consistent balanced capital

allocation strategy

• Temporarily paused our share

repurchasing program as a precautionary

measure given near-term uncertainties

• Capital expenditures estimated range for

2020 is $220 - $240 million

• Depreciation & amortization estimate for

2020 is $220 - $230 million

$96$105

$0

$50

$100

$150

YTD 2019 YTD 2020

6 mos. YTD 2020 Free Cash Flow

(in millions $)

Consolidated Financial Targets

Metric

3 Year

Average 2019 YTD 2020

Long-term

Target

Core sales growth1 5% 3% - 4% 4-7%

Adj. EBITDA2 /Sales % 20% 21% 20% 20-22%

ROIC3 13% 11% 10% 13-15%

Dividend Payout Ratio 36% 36% 42% 30-40%

Leverage Ratio ≈ 2X ≈ 2X ≈ 2X 1-3X

1 – Excludes acquisitions and currency effects.

2 – Adjusted EBITDA (earnings before net interest, taxes, depreciation and amortization) excludes restructuring costs, acquisition

costs, non-recurring purchase accounting adjustments.

3 – Return on invested capital = adjusted earnings before net interest and taxes, less tax effect / average capital (average of

beginning of year and end of year capital) [capital = equity plus debt less cash].

4 – Cash dividends paid / adjusted earnings per

share.

31

ESG

32

Stock Closure Portfolio

(PCR)Designed to Recycle Mono Material

Post Consumer

Recycled (Food grade)Circular Economy

Sustainable Solutions and Ventures

33

Exploring connected

refillable solutions

Sustainability Initiatives and Recognition

Better identifying new

material opportunities

for future products

Better measuring the

impacts of existing

products

One of Barron’s

Top 100 Most Sustainable

U.S. Companies

(2019, 2020)

We invite you to read our 2019 Corporate Sustainability Report on our website.

Designed to Recycle

Partnering with global

organizations working

toward a circular

economy

Sustainability leader in

our industry, committed

to accelerate our efforts

ESG rating of “A”

by MSCI ESG Research

LLC

34

Diversity and Inclusion

• ATR included in the SPDR® SSGA

Gender Diversity Index ETF (SHE)

• Board of Directors comprised of 40%

Women Directors

• Director Maritza Montiel named One

of the 15 Most Influential Hispanic

Leaders by Latino Leaders

• sHero Award for Best Place to Work

for Female Executives in China

• Partnering with Catalyst organization

• Workplace Survey focused on career

advancement, job satisfaction,

diversity and leadership

35

Matt DellaMariaSVP, Investor Relations & Communications

Phone: 815-479-5530Email: Matt.Dellamaria@aptar.com

36